Perigon Wealth Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.16M | Buy |
20,665
+165
| +0.8% | +$25.3K | 0.06% | 291 |
|
|
2025
Q4 | $2.83M | Buy |
20,500
+3,543
| +21% | +$464K | 0.05% | 297 |
|
|
2025
Q3 | $2.17M | Buy |
16,957
+185
| +1% | +$22.6K | 0.04% | 337 |
|
|
2025
Q2 | $2.03M | Sell |
16,772
-124
| -0.7% | -$14K | 0.05% | 324 |
|
|
2025
Q1 | $1.88M | Sell |
16,896
-350
| -2% | -$37.3K | 0.05% | 312 |
|
|
2024
Q4 | $1.69M | Sell |
17,246
-15
| -0.1% | -$1.6K | 0.04% | 338 |
|
|
2024
Q3 | $1.99M | Sell |
17,261
-220
| -1% | -$25K | 0.05% | 292 |
|
|
2024
Q2 | $1.86M | Sell |
17,481
-140
| -0.8% | -$14.1K | 0.05% | 263 |
|
|
2024
Q1 | $1.7M | Buy |
17,621
+666
| +4% | +$68.3K | 0.05% | 273 |
|
|
2023
Q4 | $1.71M | Sell |
16,955
-374
| -2% | -$36.1K | 0.06% | 249 |
|
|
2023
Q3 | $1.77M | Sell |
17,329
-54
| -0.3% | -$5.48K | 0.07% | 219 |
|
|
2023
Q2 | $1.75M | Buy |
17,383
+13,692
| +371% | +$1.37M | 0.07% | 221 |
|
|
2023
Q1 | $340K | Sell |
3,691
-81
| -2% | -$7.07K | 0.02% | 502 |
|
|
2022
Q4 | $342K | Buy |
3,772
+28
| +0.7% | +$2.36K | 0.02% | 493 |
|
|
2022
Q3 | $285K | Buy |
3,744
+135
| +4% | +$11.2K | 0.02% | 433 |
|
|
2022
Q2 | $305K | Buy |
3,609
+1,297
| +56% | +$114K | 0.03% | 427 |
|
|
2022
Q1 | $203K | Buy |
+2,312
| New | +$200K | 0.01% | 577 |
|
|
2021
Q3 | – | Sell |
-2,328
| Closed | -$212K | – | 551 |
|
|
2021
Q2 | $212K | Buy |
+2,328
| New | +$207K | 0.02% | 486 |
|
|
2021
Q1 | – | Sell |
-1,605
| Closed | -$152K | – | 854 |
|
|
2020
Q4 | $152K | Sell |
1,605
-2,195
| -58% | -$192K | 0.02% | 453 |
|
|
2020
Q3 | $330K | Buy |
3,800
+148
| +4% | +$12.8K | 0.05% | 284 |
|
|
2020
Q2 | $319K | Buy |
+3,652
| New | +$315K | 0.05% | 260 |
|
|
2018
Q2 | – | Sell |
-859
| Closed | -$65K | – | 486 |
|
|
2018
Q1 | $65K | Hold |
859
| – | – | 0.02% | 281 |
|
|
2017
Q4 | $65K | Hold |
859
| – | – | 0.02% | 259 |
|
|
2017
Q3 | $66K | Hold |
859
| – | – | 0.02% | 305 |
|
|
2017
Q2 | $64K | Sell |
859
-3,605
| -81% | -$256K | 0.01% | 352 |
|
|
2017
Q1 | $308K | Sell |
4,464
-868
| -16% | -$57.8K | 0.07% | 219 |
|
|
2016
Q4 | $363K | Buy |
5,332
+3,636
| +214% | +$236K | 0.08% | 200 |
|
|
2016
Q3 | $120K | Buy |
1,696
+550
| +48% | +$40.1K | 0.03% | 231 |
|
|
2016
Q2 | $85K | Hold |
1,146
| – | – | 0.02% | 243 |
|
|
2016
Q1 | $74K | Buy |
+1,146
| New | +$78K | 0.02% | 179 |
|
Other funds holding NVS
Perigon Wealth Management's NVS Position: Q1 2026 in Review
Perigon Wealth Management increased its Novartis (NVS) stake by 0.8% in Q1 2026, buying an estimated $25.3K and bringing the position to 20,665 shares worth $3.16M. The position accounts for 0.06% of the portfolio, ranked #291.
Perigon Wealth Management first reported a position in NVS in Q1 2016 and has held it in 30 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Perigon Wealth Management held 20,665 shares of Novartis worth $3.16M as of Q1 2026.
- Perigon Wealth Management bought 165 Novartis shares in Q1 2026, an estimated $25.3K.
- Novartis made up 0.06% of Perigon Wealth Management's portfolio in Q1 2026, its #291 holding.
- Perigon Wealth Management first reported a position in Novartis in Q1 2016 and has held it in 30 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.